Boai NKY Medical Holdings Ltd
SZSE:300109

Watchlist Manager
Boai NKY Medical Holdings Ltd Logo
Boai NKY Medical Holdings Ltd
SZSE:300109
Watchlist
Price: 16.81 CNY -2.72% Market Closed
Market Cap: 8.1B CNY
Have any thoughts about
Boai NKY Medical Holdings Ltd?
Write Note

Operating Margin
Boai NKY Medical Holdings Ltd

29.9%
Current
24%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
29.9%
=
Operating Profit
445m
/
Revenue
1.5B

Operating Margin Across Competitors

Country CN
Market Cap 8.2B CNY
Operating Margin
30%
Country SA
Market Cap 228.3B SAR
Operating Margin
3%
Country ID
Market Cap 43.8B USD
Operating Margin
-3%
Country ID
Market Cap 633.7T IDR
Operating Margin
-3%
Country US
Market Cap 28B USD
Operating Margin
4%
Country UK
Market Cap 23.9B USD
Operating Margin
7%
Country CN
Market Cap 106.9B CNY
Operating Margin
6%
Country US
Market Cap 14.6B USD
Operating Margin
7%
Country KR
Market Cap 20.2T KRW
Operating Margin
3%
Country CN
Market Cap 87.1B CNY
Operating Margin
4%
Country IN
Market Cap 885.7B INR
Operating Margin
22%
No Stocks Found

Boai NKY Medical Holdings Ltd
Glance View

Market Cap
8.2B CNY
Industry
Chemicals

Boai NKY Medical Holdings Ltd., founded in the heartland of innovation in Henan Province, China, traces its roots back to an era when the world was rapidly advancing in medical technologies yet still bustling with unmet needs for specialized medical supplies. The company pioneered its focus on producing medical polymer materials and channeled its expertise into the creation of polyvinyl pyrrolidone (PVP), a versatile substance used in pharmaceuticals, cosmetics, and various medical applications. This single compound laid the foundation for the firm's ascent, offering it the placement in the global market where its robust application spans from being a pharmaceutical binder to a blood plasma substitute. The magic of Boai NKY lies in its ability to marry scientific research with commercial execution, ensuring its products meet stringent international standards, thereby opening doors to markets in over 50 countries. The company generates revenue by leveraging its strong manufacturing capabilities and R&D investments. This ensures a steady stream of innovative products catering to the global health industry. Boai NKY's business model diversifies risk by spreading its expertise across biomedicine, cosmetics, agriculture, and food sectors, creating a symbiotic revenue framework. By maintaining a diverse product portfolio and nurturing strategic partnerships, the company builds resilience against market volatility and economic downturns. Its revenue is bolstered not only by domestic sales but by a prominent international presence supported by a network of subsidiaries and distributors. This global footprint ensures a stable cash flow, while continuous investment in technology and quality assurance sustains Boai NKY at the forefront of the competitive chemical manufacturing landscape.

Intrinsic Value
12.92 CNY
Overvaluation 23%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
29.9%
=
Operating Profit
445m
/
Revenue
1.5B
What is the Operating Margin of Boai NKY Medical Holdings Ltd?

Based on Boai NKY Medical Holdings Ltd's most recent financial statements, the company has Operating Margin of 29.9%.